This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Background: The purpose of this study is to find out whether long-term treatment with pegylated-interferon (PEG-IFN) slows the rate of liver damage caused by hepatitis C in people also infected with HIV.
Specific Aims and Procedures (summary): Part 1: Participants will be given PEG-IFN and ribavirin for 12 weeks if they have never been treated for HCV; they have been treated in the past with PEG-IFN, IFN or IFN and ribavirin for up to one year, but have been off treatment for 12 weeks; or they have been treated with some form of IFN for at least 12 weeks and still have HCV. After 12 weeks of treatment, all participants will have a liver biopsy. Part 2: Participants who do not show signs of responding to the 12 weeks of treatment will be assigned by chance to either receive PEG-IFN alone for 72 weeks or to continue on study off treatment for 72 weeks.Part 3: Participants who sign signs of responding to the 12 weeks of treatment will continue to receive PEG-IFN and ribavirin for 72 weeks and then be followed on study for an additional 24 weeks off treatment. Significance (summary): Study findings will be available to participants.
Showing the most recent 10 out of 465 publications
